Quantcast

Latest Hepacivac Stories

2014-10-22 08:31:10

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct. 22, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned,...

2014-07-01 12:27:54

- Results Confirm Efficacy and Safety of an All-Oral combination of Mogrovir(TM) with Ribavirin(TM) in Genotype 1, Therapy Naive HCV Patients. LOS ANGELES, July 1, 2014 /PRNewswire/ -- Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM)...

2014-06-18 12:29:54

Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON, Mass., June 18, 2014 /PRNewswire/ -- Decision Resources Group finds that China's market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated population, following the introduction of novel HCV therapies. Nearly a third of patients diagnosed with HCV do not receive the...

2014-05-29 08:29:27

SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it has dosed the first patient in its 'first in man', Phase I/IIa clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection. Benitec Biopharma's CEO and Managing Director, Peter French said, "The commencement of this clinical trial of TT-034 represents a landmark in the Company's...

2014-05-21 12:49:39

American Chemical Society To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way. Now scientists are solving another side of the disease's problem: identifying the millions more who have the virus but don't know it — and unwittingly pass it on. A report in the ACS journal Analytical Chemistry describes a novel, scrapbook-inspired test that does just that. Xuan Mu, Zhi Zheng...

2014-05-19 10:12:50

University at Buffalo More effective, new medications for HCV infection with fewer side effects also are causing a shift in patients’ attitudes People who inject drugs and are enrolled in a drug treatment program are receptive to education about, and treatment for, hepatitis C virus, according to a study by researchers at several institutions, including the University at Buffalo. That finding, published online this week in the Journal of Addiction Medicine will be welcome news to...

2014-04-22 08:34:00

-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by...

2014-03-25 08:29:46

NEW YORK, March 25, 2014 /PRNewswire/ -- At the New York Viral Hepatitis Summit presented by the National Black Leadership Commission on AIDS, Inc. (NBLCA) on Thursday, March 20 at Harlem Hospital Center in New York City, medical experts, public health officials, and community health advocates discussed the latest medical research, diagnosis and treatment options, and community health implications of the Hepatitis C virus (HCV), emphasizing the disproportionate impact of HCV on the...

2014-03-06 08:30:17

Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March 6, 2014 /PRNewswire/ -- Today Boehringer Ingelheim announced results from STARTVerso(®)4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg...

Hepatitis C Vaccine Efforts Bring Vaccine Closer To Reality
2013-11-30 05:22:41

redOrbit Staff & Wire Reports - Your Universe Online A hepatitis C vaccine is one step closer thanks to the efforts of scientists at The Scripps Research Institute (TSRI), who have managed to discover unexpected structural features of a protein used by the virus to infect liver cells. The study authors, whose work appears in Friday’s edition of the journal Science, state any successful hepatitis C vaccine would most likely target this protein, which is known as E2 envelope...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.